Abstract 231P
Background
Body mass index (BMI) has shown the associated with clinical outcomes of immune checkpoint inhibitors (ICIs) treatment in patients with several malignancies. We previously reported the association between clinical outcome in advanced urothelial carcinoma (UC) patients treated with pembrolizumab and BMI according to the WHO international classification. However, no patient in our cohort was grouped into obese (BMI 30kg/m2≤) and WHO BMI classification may be unsuitable for Asians. Therefore, we investigated the association between BMI classification developed for Asian people and clinical outcomes of pembrolizumab for advanced UC.
Methods
We retrospectively reviewed consecutive patients with advanced UC who received pembrolizumab between December 2003 and March 2023. Patients were divided into three groups based on BMI classification for Asians; the non-overweight group (BMI < 22.9 kg/m2), the overweight group (23 ≤ BMI < 24.9 kg/m2), and the obese group (BMI ≥ 25 kg/m2). Tumor response, progression-free survival (PFS), overall survival (OS), and incidence of adverse events (AEs) were compared among the groups. We additionally investigated factors associated with PFS using the multivariate analysis.
Results
Of 99 eligible patients, 54 (54.5%), 21 (21.2%) and 24 (24.2%) were in the non-overweight, overweight and obese group, respectively. PFS was significantly longer in the obese group (median 10.3 months) than that in the non-overweight (median 4.2 months) and the overweight group (median 2.3 months) (p=0.04). Multivariate analysis showed that obese was significantly associated with favorable PFS. The obese group had higher objective response rate and longer OS compared to other groups, although the difference did not reach the statistical significance. Multivariate analysis showed that obese was significantly associated with favorable PFS. There was no difference in the occurrence of irAEs among three groups.
Conclusions
BMI was associated with PFS for patients with advanced UC received pembrolizumab and BMI Asian classification may be more useful and suitable for Asian patients than that of WHO classification.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract
27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Presenter: Asako Tsuruga
Session: Poster Display
Resources:
Abstract
28P - One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
Presenter: Nurilla Zaynutdinov
Session: Poster Display
Resources:
Abstract
30P - Stereotactic body radiotherapy using cyberknife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of preliminary clinical result and dosimetric characteristics
Presenter: Ting-Na Wei
Session: Poster Display
Resources:
Abstract
31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer
Presenter: Ki-tae Hwang
Session: Poster Display
Resources:
Abstract
32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Presenter: Manami Tada
Session: Poster Display
Resources:
Abstract
34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Presenter: Nithiya Sinarajoo
Session: Poster Display
Resources:
Abstract
35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Presenter: Winnie Yeo
Session: Poster Display
Resources:
Abstract
37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients
Presenter: Clarisse Hing
Session: Poster Display
Resources:
Abstract
38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data
Presenter: Lv Wenjie
Session: Poster Display
Resources:
Abstract